The Role of Impella in Cardiogenic Shock in the Post-DanGer Shock Era
Bibliographic record
Abstract
The microaxial flow pump (mAFP) is a mechanical circulatory support device designed to directly unload the left ventricle, restore cardiac output, and improve systemic perfusion in the setting of cardiogenic shock (CS). CS is a devastating complication of acute myocardial infarction (AMI) and advanced heart failure, characterized by systemic hypoperfusion and myocardial dysfunction, carrying an in-hospital mortality of 30-50%. However, there has been controversy about whether these theoretical physiological mechanisms behind mAFP translate into actual survival or recovery in this patient population that has historically been difficult to study in prospective trials. The lack of consensus has resulted in differing national guidelines, resource allocation, and clinical decision-making in time-sensitive clinical scenarios. Earlier studies were limited to retrospective analyses and a single small, underpowered randomized trial, none of which showed a mortality benefit. In 2024, the DanGer Shock trial emerged as the first multi-center trial to demonstrate mortality benefit in patients with STEMI complicated by CS treated with Impella CP, albeit at the cost of increased risk of major bleeding, hemolysis, and vascular complications, an effect sustained in the 10 year outcomes published in 2025. In this review, we examine reasons for the differing results of preceding studies and compare how multinational guidelines have reacted to this new evidence. Finally, we provide practical considerations regarding the use, complications, and troubleshooting of this technology, and identify gaps in evidence regarding patient selection and timing of placement.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.008 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".